Its obvious the possible mistakes in the Annual Financials are not an issue to some, but it is for me considering that these documents are prepared by "professionals" with "experience" in these fields and audited by an independent.
Over payment (shares in lieu of cash) is not acceptable in any way, shape or form re: post
29211842
As for being critical of a person's use of grammar is a shallow attempt at trying to take away the reason for the post, that being, there are flaws in the company's financials as far back as pre IPO and listing on the ASX.
Again, it may not be a concern for some and bringing these topics to the thread obviously gets up a few posters noses because it doesn't align with their view of everything being honky dory at GPP, but it is a concern for me and as such I have sent an email expressing as much.
This "possible" mistake in reporting (3Y's) or the Annual Report isn't from 2008/2009 or any subsequent years, it is from the year ending 30th June 2017.......
View attachment 862169
http://www.asx.com.au/asxpdf/20161118/pdf/43d0m1s0vbpmtb.pdf
View attachment 862187
A total of 5,500,000 shares were sold "as above".
As highlighted, the Annual Report has only 5,000,000.
View attachment 862196
http://www.asx.com.au/asxpdf/20170926/pdf/43mmywbppywfyr.pdf
And NO, I haven't topped up, the last time I purchased shares in GPP was early in the year as well as I have previously indicated that I will purchase more
if/when the OHD project's direction is defined.
No doubt they will be at a premium to the current share price but the magnitude of the Bio-stimulant project could be a game changer for GPP and as such it will compensate handsomely for any premiums paid to secure more shares.
All the above is IMO only
